General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1 — At a Glance
Hikal closed the June 2026 quarter with consolidated revenue of ₹403 Cr, up 5.9% on the same quarter last year. Operating profit was ₹37 Cr against ₹25.1 Cr a year ago. The bottom line was a loss of ₹7.4 Cr, against a loss of ₹22.4 Cr in Q1 FY26.
The quarter also carried an exceptional item in the unusual direction: ₹9 Cr of income, arising from a reversal of the excess provision the company had booked earlier for the new labour codes, after it restructured salary components. Last year’s exceptional line went the other way — ₹85 Cr of charges across the labour-code provision and a ₹47 Cr impairment at Panoli.
Segment-wise, Pharmaceuticals did ₹233 Cr of revenue with ₹8 Cr of EBIT. Crop Protection did ₹170 Cr with EBIT of negative ₹6 Cr. Management attributes the crop margin hit to roughly ₹7–8 crore of raw-material cost increase within the single quarter, arising from geopolitical developments across input costs.
Sitting over all of it is the US FDA warning letter issued to the Jigani site in August 2025, which the company’s own filing states has impacted Pharma segment sales for the periods presented. Management describes remediation as being at the penultimate stage, with reinspection expected during the current financial year.
Capex in the quarter ran about ₹45 crore, directed at debottlenecking, regulatory upgrades and new capacity. A company mid-way through a regulatory clean-up was still buying equipment.
Hold that thought. The four-year capex figure is coming.
2 — Introduction
Hikal was incorporated in July 1988 as Hikal Chemicals Industries Private Limited, founded by the Hiremath family alongside Surajmukhi Investments & Finance Limited, a wholly owned subsidiary of Kalyani Steels. It listed in 1995 and took its present name in 2000. Thirty-eight years later, it supplies research services, active ingredients and intermediates across pharmaceuticals, crop protection and specialty chemicals.
The recent chronology is dense. In February 2025, the USFDA inspected the Jigani, Bengaluru site over five days and closed with six observations. On 21 May 2025, the site was classified Official Action Indicated. On 21 August 2025 the FDA issued a warning letter, citing inadequate investigation of customer complaints relating to foreign matter and gaps in vendor management. Hikal responded on 11 September 2025 stating several corrective actions were already implemented.
Separately, in December 2025, the company disclosed irregularities and alterations in supporting documentation, primarily around revenue recognition. Sales had been increased by roughly ₹80 crore across Q4 FY25 and Q1 FY26; ₹80.7 Cr was reversed in Q2 FY26. The suspected misconduct involved certain employees across Sales & Marketing, Logistics and allied functions. On 27 May 2026 the company disclosed that its fraud review showed no financial impact and that employees had been relieved, alongside the appointment of Ravi Khadabadi as President–Crop Protection.
ICRA downgraded the long-term rating from A+ to A and the short-term rating from A1 to A2+ on 24 November 2025, citing the USFDA OAI and warning letter. The February 2026 rating action kept both at [ICRA]A (Stable) and [ICRA]A2+ while resizing the facility limits.
Also in the quarter: an EcoVadis Gold rating, 84/100, placing the company in the top 5% of over 175,000 assessed companies.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3 — Business Model: WTF Do They Even Do?
Hikal makes the molecules that go inside other people’s branded boxes. Nobody buys a Hikal-branded anything. The company supplies APIs, intermediates and advanced intermediates to pharmaceutical companies, and active ingredients plus custom-synthesised chemistry to crop protection majors. It’s the supplier your supplier thanks in the annual report.
The physical footprint: five manufacturing facilities across three states, 24 production blocks, 3,000-plus employees. Pharmaceuticals runs Jigani Unit 1 and Unit 2 in Karnataka and Panoli in Gujarat, totalling 1,600 m³ of reactor capacity. Crop Protection runs Taloja and Mahad in Maharashtra plus its own block at Panoli, totalling 2,500 m³. The Panoli site was bought from Novartis in 2000 and is US FDA-approved for KSMs and APIs. The Taloja plant, per ICRA, is the only fully integrated plant in the world producing Thiabendazole — a sentence that sounds like a boast until you realise it means the global supply of a fungicide runs through one address in Raigad district.
The FY26 revenue split was Pharmaceuticals 60%, Crop Protection 40%. Within pharma, CDMO was 52% and Own Products 48%. Within crop, CDMO was 65%. The portfolio carries 86 active DMFs and 31 commercialised APIs on the pharma side, and 30 commercialised products on the crop side.
Two newer divisions are being built into the frame. Animal Health, run out of a Panoli multi-purpose facility with 145 m³ of reactor capacity, covers 10-plus APIs, 30-plus chemistries and seven animal species in companion animals. Management states it did over ₹100 Cr of turnover last year
